Nielsen T L, Jensen B N, Nelsing S, Pedersen C, Mathiesen L R, Skinhøj P, Nielsen J O
Department of Infectious Diseases, Hvidovre Hospital, Copenhagen.
Dan Med Bull. 1993 Sep;40(4):503-5.
The effectiveness and tolerability of Sulfamethoxazole with Trimethoprim (SMX-TMP), a dose of 400mg/80mg given twice a day as secondary prophylaxis (SP) against Pneumocystis carinii pneumonia (PCP) was assessed retrospectively in 166 AIDS patients. The mean observation period was 9.7 months (range 1.0-1.4). Relapse of PCP occurred in eight patients; four episodes were histologically verified and four episodes were clinically assumed. The relapse rate after one year of prophylaxis was 5.1% (95% CI 0.0%-11.0%) using the log-rank test. Intolerance of secondary prophylaxis, defined as adverse effects necessitating cessation of SP with SMX-TMP, was reported in eight patients (5%) (95% CI 2.1%-9.3%).
对166例艾滋病患者进行回顾性评估,以400mg/80mg剂量的复方磺胺甲恶唑(SMX-TMP)每日两次作为预防卡氏肺孢子虫肺炎(PCP)的二线预防用药(SP)的有效性和耐受性。平均观察期为9.7个月(范围1.0 - 1.4年)。8例患者发生PCP复发;4例经组织学证实,4例为临床推测。使用对数秩检验,预防一年后的复发率为5.1%(95%可信区间0.0% - 11.0%)。8例患者(5%)(95%可信区间2.1% - 9.3%)报告了二线预防不耐受情况,定义为因不良反应而必须停用SMX-TMP进行二线预防。